A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination with Anticancer Agents Including Pembrolizumab in Adult Participants with Selected Adva

Protocol: 
AAAS1446
Phase: 
I/II

A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination with Anticancer Agents Including Pembrolizumab in Adult Participants with Selected Adva

GSK3145095 inhibits receptor interacting protein 1 (RIP1) which may affect your
immune system’s response (ability to fight) to your cancer. GSK3145095 is not yet
FDA approved for use in humans. This study is the first time that GSK3145095 is
being given to people. This research study is being done to learn more about your
cancer and if GSK3145095 can improve your cancer/make you feel better. You are
expected to stay on study treatment for up to 2 years. This study may include up to
220 study participants. We also would like to answer the following question such as
is GSK3145095 safe, how well does GSK3145095 work to treat people with your cancer
and related conditions, what dose(s) of GSK3145095 works best and how

Are you Eligible? (Inclusion Criteria)

1) Are you age 18 or older?

2) Are you willing to provide fresh tissues?

3) Have you been diagnosed with pancreatic ductal adenocarinoma (PDAC)

4) Do you have life expectancy of at least 12 weeks?

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States